Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-08-29
2006-08-29
Stucker, Jeffrey (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S007100, C435S974000, C435S975000, C530S324000, C530S325000, C530S326000, C530S329000, C530S826000, C424S188100, C424S193100, C424S196110, C424S208100
Reexamination Certificate
active
07097971
ABSTRACT:
The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV Tat and Rev, regulatory proteins and Nef, auxiliary proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
REFERENCES:
patent: 5595884 (1997-01-01), Androphy et al.
patent: 6706859 (2004-03-01), Sörensen
patent: 2004/0259797 (2004-12-01), Sorensen
patent: 2773156 (1999-07-01), None
patent: 94/15634 (1994-07-01), None
patent: 9415634 (1994-07-01), None
patent: 9627389 (1996-09-01), None
patent: 99/02185 (1999-01-01), None
patent: 9902185 (1999-01-01), None
patent: 99/27958 (1999-06-01), None
patent: 9927958 (1999-06-01), None
patent: 0078969 (2000-12-01), None
Goldstein, “HIV-1 Tat protein as a potential AIDS vaccine”, Nature Medicine, vol. 2, No. 9 (Sep. 1996), pp. 960-964.
Riffkin et al. “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 fromDichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. “Effect of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”, Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp. 433-444.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Cohen et al. “Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge”, Proceedings of the National Academy of Sciences of the United States of America, vol. 96, Issue 19(Sep. 14, 1999), pp. 10842 10847.
Blazevic et al., Aids Research and Human Retroviruses, vol. 11, No. 11, 1995, pp. 1335-1342.
G. Goldstein, “HIV-1 Tat protein as a potential AIDS vaccine”, Nature Medicine, vol. 2, No. 9, Sep. 1996, pp. 960-964.
Bionor Immuno AS
Stucker Jeffrey
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
HIV-1 peptide, antigen, immunogenic composition, diagnostic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-1 peptide, antigen, immunogenic composition, diagnostic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 peptide, antigen, immunogenic composition, diagnostic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655569